Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigms ACL Phase 2 Clinical Trial Success
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- PAR Successfully Completes A$5.75m Placement
- First Participant Dosed in PARs Phase 2b OA Clinical Trial
- PAR reports pain reduction in 83% of osteoarthritis patients
- PARs Osteoarthritis Phase 2 Receives Ethics Approval
- Paradigm Phase 2 Ross River Virus Clinical Trial Update
Later from Paradigm Biopharmaceuticals
- Paradigms Two Arthritis Phase 2 Clinical Trials on Schedule
- PARs European Patent Granted for Bone Marrow Edema Lesions
- Quarterly Update and Appendix 4C
- Half Year Accounts
- Paradigm reports osteoarthritis pain reduced by 50%
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals